tiprankstipranks
Trending News
More News >

Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank

Scotiabank analyst Sung Ji Nam raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $12 from $10 and keeps an Outperform rating on the shares. The company ended FY24 on a “strong note,” beating expectations across the board, the analyst tells investors. The firm continues to think there is significant growth potential ahead for the company’s minimal residual disease business.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue